China-Singapore Jingwei, August 9. According to the news on the website of the National Medical Insurance Bureau on the 9th, recently, the National Medical Insurance Bureau, together with relevant departments, will guide the relevant provinces on

Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. according to relevant clues.

The company's Baiyunshan Pharmaceutical General Factory and Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co.

, Ltd. and other three enterprises

conducted special investigations by

inflating drug prices and defrauding funds .

  According to investigations, from 2017 to May 2021, in order to circumvent the "two-invoice system" policy and supervision, three drug manufacturers including Tianxin Pharmaceuticals colluded with more than 50 downstream drug agents, and colluded with more than 50 downstream drug agents to collude with 87 kinds of drugs including cefathiamidine for injection. Drugs are cashed out by purchasing APIs at inflated prices and transferring funds to downstream drug agents.

The amount involved is huge, and some of the funds are used to bribe medical staff or specific related persons to carry out illegal promotion of drugs.

  The main method of cashing out is that drug manufacturers and drug agents sign a cooperation agreement to add designated "distributors" in the procurement of APIs, and the "dealers" buy APIs at normal prices, increasing the price several times to ten times. It is sold to pharmaceutical manufacturers several times.

In the name of "rising prices of raw materials and high production costs", pharmaceutical manufacturers have further transmitted the falsely high prices of raw materials to factory and bidding prices.

The “dealers” of APIs are actually controlled by the pharmaceutical agents, and they cash out the income from the price difference obtained by buying low and selling APIs high, and transfer them to the pharmaceutical agents for them to implement pharmaceutical commercial bribery.

Taking cefathiamidine for injection as an example, Baiyunshan Pharmaceutical (preparation factory) and Baiyunshan chemical pharmaceutical factory (raw material factory) belong to the same group, but the cefathiamidine raw material required by the preparation factory is not directly purchased from the raw material factory of the group. Instead, an additional cash-out process is set up, and the “distributors” of APIs controlled by agents change hands, buy low and sell high to preparation factories and cash out.

The preparation factory used the high cost of raw materials to cover the artificially high price of cefathiamidine for injection, which made the production and circulation of the drug ostensibly comply with the "two-invoice system" and other policies and regulations, evading supervision.

  At present, Tianxin Pharmaceutical and other 3 companies have rectified the prices of 87 kinds of drugs including cefathiamidine for injection involved nationwide as required,

excluding the falsely high part of the current price used for bribery, with an average reduction of more than 50%, and some The product specification was discontinued

.

Guangdong Province ordered three companies including Tianxin Pharmaceutical and other related companies to comprehensively rectify their marketing models and stop related illegal operations.

In addition, the relevant departments are investigating and punishing those suspected of violating discipline, law and crime.

  The National Medical Insurance Bureau stated that it will continue to guide the provinces with relevant departments, according to the implementation of corporate rectification and the facts of violations of laws and regulations identified by relevant departments, to do a good job in the evaluation of pharmaceutical prices and recruitment credit, and to cooperate with relevant departments to continue to correct the unhealthy areas of pharmaceutical purchase and sales. wind.

The majority of pharmaceutical production and operation enterprises should take this as a warning, take the initiative to regulate their own business operations, abide by the statutory pricing principles of fairness and reasonableness, honesty and credit, and consistent quality and price, and work together to create a clean market environment and industry ecology.

  According to the Tianyancha APP, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. was established in 1993 with a registered capital of 45.693 million yuan. It is a

member

of GPHL and is located in Guangzhou, Guangdong Province. It is an enterprise mainly engaged in pharmaceutical manufacturing.

  Guangzhou Baiyunshan Pharmaceutical Factory was founded in 1973. It is

the largest pharmaceutical industry enterprise under GPHL

and the largest specialized antibiotic manufacturer in South China. It integrates R&D, production and sales. Two "China Famous Brands", the annual sales revenue exceeds 2 billion yuan.

  Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co., Ltd. is

one of the main Chinese patent medicine manufacturing enterprises under GPHL

. Founded in 1790, it has more than 140 varieties of various Chinese patent medicines, chemical medicines and health tonics.

  According to the official website, Guangzhou Pharmaceutical Group Co., Ltd. (Guangzhou Pharmaceutical Group) is a state-owned enterprise authorized by the Guangzhou Municipal Government to operate and manage state-owned assets. Research and development, production and sales, as well as the provision of medical and health care services, is a large-scale enterprise group integrating science, industry and trade, which is supported by Guangzhou City.

  Source: GPHL official website

  In addition to the three companies investigated this time, GPHL's subsidiaries also include Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd., Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd., Guangzhou Baiyunshan Pangaoshou Pharmaceutical Co., Ltd., etc. .

  According to the 2021 Fortune Global 500 list, GPHL is on the list for the first time, ranking 468th, becoming the first company in the world to enter the world's top 500 companies with traditional Chinese medicine as its main business.

(Sino-Singapore Jingwei APP)